| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2019/007 | ||
|---|---|---|---|
| Date of filing | 15/02/2019 | ||
| Notification of Application Published | 20/03/2019 | ||
| Status | Granted | ||
| Notification of Grant Published | 05/02/2020 | ||
| Date of Expiry of SPC | 26/08/2033 | ||
| Applicant |
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia, PA 19104-6283 UNITED STATES OF AMERICA |
||
| Patent Number | 2649086 | ||
| Title of Invention | USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER | ||
| Date of Expiry of Patent | 08/12/2031 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Tisagenlecleucel | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/18/1297 | ||
| Authorisation Date | 23/08/2018 | ||
| Identity of Product Authorised | Kymriah-tisagenlecleucel | ||
| Address for Service |
MACLACHLAN & DONALDSON (IRELAND) LIMITED, trading as MACLACHLAN & DONALDSON Unit 10, 4075 Kingswood Road Citywest Business Campus Dublin 24 D24 C56E IRELAND |
||
| Renewal Fees | |||
| 15/01/2020 | Supplementary Protection Certificate Number 2019/007, having an expiry date of 26/08/2033 granted on 15/01/2020. | ||